Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases-Reference-Cited by-同舟云学术

Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases

Published:2012-01 Issue:1 Volume:2 Page:
ISSN:2190-9164
Container-title:Biologics in Therapy
language:en
Short-container-title:Biol Therapy

Author:

Sophie Raafay,Akhtar Abeer,Sepah Yasir J.,Ibrahim Mohamed,Bittencourt Millena,Do Diana V.,Nguyen Quan Dong

Publisher

Springer Science and Business Media LLC

Link

http://www.springerlink.com/index/pdf/10.1007/s13554-012-0003-4

Reference107 articles.

1. Augood C, Fletcher A, Bentham G, et al. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol. 2004;11:117-29.

2. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900-1.

3. Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-72.

4. Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844-51.

5. Congdon N, O’Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-85.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microvolume Analysis of Aflibercept in Aqueous Humor Using Mass Spectrometry;Translational Vision Science & Technology;2022-06-07

2. Intravitreal hydrogels for sustained release of therapeutic proteins;Journal of Controlled Release;2020-10

3. Preclinical challenges for developing long acting intravitreal medicines;European Journal of Pharmaceutics and Biopharmaceutics;2020-08

4. EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION;Retina;2020-07

5. Anti‐VEGF‐Aptamer Modified C‐Dots—A Hybrid Nanocomposite for Topical Treatment of Ocular Vascular Disorders;Small;2019-08-12